The FDA has approved a higher weekly dose of Wegovy (semaglutide) at 7.2 mg. While clinical trials show this 3× increase can drive total body weight loss toward 20.7%, it also raises the risk of dose-dependent side effects like dysesthesia and GI distress. With no official titration guidelines yet available, Dr. Joshua Silva discusses how to approach this new dosage safely and who may benefit most from the increase.

Early research from the 2026 AAOS Annual Meeting indicates that GLP-1 medications like Ozempic and Wegovy may be associated with a higher relative risk of tendon ruptures. However, with an absolute risk increase of less than 1%, most patients remain unaffected. Discover the proposed mechanisms—from rapid activity increases to collagen signaling—and how to mitigate risk while continuing therapy.